Select to order medicines [Delhi/NCR /Bangalore /Chennai /Bhubaneswar /Mumbai]
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
There is positive evidence of risk to a breastfed infant or to breastmilk production, but the benefits of use in breastfeeding mothers may be acceptable despite the risk to the infant (e.g. if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Typical usage: Essential hypertension.
Side Effects: Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, hypotension, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial edema, angioedema, and rhabdomyolysis.
Drug Interaction: Concurrent use with ACE inhibitors, potassium-sparing diuretics, potassium salts, and drugs that may increase serum potassium (e.g. ciclosporin, eplerenone) may increase the risk of hyperkalaemia. Concomitant use with NSAIDs may decrease glomerular filtration synergistically; acute renal failure may occur. Increased serum concentrations of lithium and toxicity when used with angiotensin receptor antagonist have been reported; avoid concomitant use of lithium and Olmesartan medoxomil.
Mechanism Of Action: Olmesartan medoxomil is an ester prodrug for olmesartan. It is hydrolysed to olmesartan during absorption from the GI tract. Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist and hence it blocks the vasocontrictor and aldosterone-secreting effects of angiotensin II.
Showing 5 of 46
Showing 5 of 46